EndoTODAY | EndoATLAS | ¿Ü·¡¼³¸íÀÚ·á

±â»ýÃæ | ½Äµµ | À§ | À§¾Ï | ESD | õ±â´©¼³

Home | Guide | ÁÖÀÎÀå | ±¸µ¶ | °Ë»ö | ¸µÅ©


[ÀÏ¿ø³»½Ã°æ±³½Ç ¸ñ¿äÁ¡½ÉÁý´ãȸ 2016-2-4]

Previous | Next

1. À§¾Ï life cycle

ÀÇ·Ú Àü ³»½Ã°æ °Ë»ç¿Í ÀÇ·Ú ÈÄ ³»½Ã°æ °Ë»ç¿¡¼­ ¸ð¾çÀÌ »ç¹µ ´Ù¸¥ °æ¿ì°¡ ÀÖ½À´Ï´Ù. ÀÌÀ¯´Â ´ë°­ 3°¡Áö ÀÔ´Ï´Ù. (1) À§¾Ï Áø´Ü ÈĺÎÅÍ ¾àÀ» º¹¿ëÇÏ´Â »ç¶÷ÀÌ ¸¹½À´Ï´Ù. (2) Á¶Á÷°Ë»ç ÈÄ ¸ð¾çÀÌ º¯ÇüµÉ ¼ö ÀÖ½À´Ï´Ù. (3) À§¾ÏÀº life cycleÀÌ ÀÖ½À´Ï´Ù.

Stomach, total gastrectomy:
Advanced gastric carcinoma
1. Location : middle third, Center at mid body and posterior wall
2. Gross type : Borrmann type 3
3. Histologic type : tubular adenocarcinoma, poorly differentiated
4. Histologic type by Lauren : diffuse
5. Size : 3.8x2.4 cm
6. Depth of invasion : invades serosa (pT4a)
7. Resection margin: free from carcinoma, safety margin: proximal 4 cm, distal 11.8 cm
8. Lymph node metastasis : no metastasis in 78 regional lymph nodes (pN0)
9. Lymphatic invasion : not identified
10. Venous invasion : not identified
11. Perineural invasion : present
12. Peritoneal cytology : negative
13. AJCC stage by 7th edition: pT4a N0


2. Mucinous adenocarcinoma

º¸¸¸ 2ÇüÀϱî¿ä ȤÀº º¸¸¸ 1ÇüÀϱî¿ä? °í¹ÎµÇ´Â Áõ·ÊÀÔ´Ï´Ù. º¸Åë 2ÇüÀ¸·Î ºÎ¸£´Â °Í °°½À´Ï´Ù.

Stomach, radical subtotal gastrectomy:
Advanced gastric carcinoma
1. Location : lower third, Center at lower body and anterior wall
2. Gross type : Borrmann type 2
3. Histologic type : mucinous adenocarcinoma (mucin production: 60%) with signet ring cell feature
4. Histologic type by Lauren : diffuse
5. Size : 4x4 cm
6. Depth of invasion : penetrates subserosal connective tissue (pT3)
7. Resection margin: free from carcinoma, safety margin: proximal 3.5 cm, distal 3.5 cm
8. Lymph node metastasis : no metastasis in 39 regional lymph nodes (pN0)
9. Lymphatic invasion : present
10. Venous invasion : not identified
11. Perineural invasion : not identified
12. AJCC stage by 7th edition: T3 N0


3. Poorly differentiated neuroendocrine carcinoma

¼ö¼ú Àü Á¶Á÷°Ë»ç·Î Á¤È®È÷ Áø´ÜÇϱ⠾î·Á¿î Á¾·ùÀÔ´Ï´Ù.

Stomach, subtotal gastrectomy:
Poorly-differentiated neuroendocrine carcinoma (G3)
1. Name of Procedure: Organ resection
2. Site of Tumor: Stomach (Antrum)
3. Diagnosis: Neuroendocrine carcinoma (G3)
4. WHO classification(2010): Poorly differentiated neuroendocrine carcinoma, large cell type
5. Multiplicity: Single
6. Size: 6x6 cm
7. Extent: Serosa
8. Grading: Mitotic Count(/10HPF): >20 (about 60/10 HPF)
9. Immunohistochemical Stains:
1) Synaptophysin : Positive
2) Chromogranin A: Negative
3) OPTIONAL : CD56 (+)
10. Lymphovascular invasion: present
11. Perineural invasion: present
12. Lymph node metastasis: [Number of positive nodes/Total number of nodes(7/32)
13. Resection Margins: Negative,Safety margin : proximal 3.5 cm, distal 3 cm
14. Other Pathologic Components: Presence of tumor necrosis (60 %)


4. Signet ring cell carcinoma of the rectum

Àܺ¯°¨À» ÁÖ¼Ò·Î ´ëÀå³»½Ã°æÀ» ÇÑ È¯ÀÚÀÔ´Ï´Ù. ´ëÀå³»½Ã°æ¿¡¼­ soft, nodular, submucosal lesionµéÀÌ upper rectum¿¡¼­ ¹ß°ßµÇ¾î submucosal tumor³ª infiltrative disease¸¦ °¨º°ÇÏ¿´´Âµ¥ Á¶Á÷°Ë»ç¿¡¼­ signet ring cell carcinoma with lymphatic spaces, either primary or metastaticÀÇ °á°ú¿´½À´Ï´Ù. Staging work up¿¡¼­ LN, soft tissue, bone metastasis°¡ ÀÖ¾î FolFIRI º¹ÇÕÇ×¾ÏÄ¡·á ½ÃÀÛÇÏ¿´½À´Ï´Ù.


5. Eosinophilic colitis

CBC¿¡¼­ WBC 18,660 (eosinophil 44.4%), Á÷Àå°ú ´ëÀå Á¶Á÷°Ë»ç¿¡¼­ focal colitis with eosinophilic infiltrationÀ¸·Î ³ª¿Í eosinophilic colitis·Î Áø´ÜÇÏ¿´½À´Ï´Ù.

Primary eosinophilic gastrointestinal disorders (EGIDs) represent a spectrum of inflammatory gastrointestinal disorders in which eosinophils infiltrate the gut in the absence of known causes for such tissue eosinophilia.

EGIDs can be subgrouped as eosinophilic esophagitis (EE), eosinophilic gastroenteritis (EG), and eosinophilic colitis (EC). The least frequent manifestation of EGIDs is EC. EC is a heterogeneous entity with a bimodal age distribution, presenting with either an acute self-limited bloody diarrhea in otherwise healthy infants or as a more chronic relapsing colitis in young adults.

The pathophysiology of primary EC appears related to altered hypersensitivity, principally as a food allergy in infants and T lymphocyte-mediated (i.e. non-IgE associated) in young adults. In adults, symptoms include diarrhea, abdominal pain, and weight loss. Endoscopic changes are generally modest, featuring edema and patchy granularity. Although standardized criteria are not yet established, the diagnosis of EC depends on histopathology that identifies an excess of eosinophils. Therapeutic approaches are based on case reports and small case series, as prospective randomized controlled trials are lacking. Eosinophilic colitis in infants is a rather benign, frequently food-related entity and dietary elimination of the aggressor often resolves the disorder within days. Adolescent or older patients require more aggressive medical management including: glucocorticoids, anti-histamines, leukotriene receptors antagonists as well as novel approaches employing biologics that target interleukin-5 (IL-5) and IgE.

Âü°í¹®Çå: Eosinophilic colitis: epidemiology, clinical features, and current management. Therap Adv Gastroenterol. 2011 Sep;4(5):301-9

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà